Bristol Myers signs $380 million CAR-T therapies supply deal with
Cellares
Send a link to a friend
 [April 22, 2024]
(Reuters) -Drugmaker Bristol Myers Squibb said it has signed a
$380 million deal with contract manufacturer Cellares to manufacture its
CAR-T cell therapies in the United States, EU and Japan.
The collaboration will help Bristol Myers to expand its manufacturing
capacity due to increasing demand. The company said in February it was
looking to launch both its CAR-T blood cancer therapies Abecma and
Breyanzi in a number of new countries this year.
CAR-T therapy involves removing a patients' own T cells - a key
component of the immune system - engineering them to recognize and
attack malignant cells, and re-infusing them.
(Reporting by Christy Santhosh; Editing by Shinjini Ganguli)
[to top of second column]
|
A sign stands outside a Bristol Myers Squibb facility in Cambridge,
Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
